gretel
20 Jul 2016
Moving up nicely today Nice - £1,200 of net buys today is enough to send the share price up 1.5p (and close the published spread somewhat too).Online you can now sell 150,000 at 10.25p, and only buy a maximum 5,000 at 12p.Looking extremely encouraging.
gretel
14 Jul 2016
Re: Good buying interest online Even better online now.Currently you can sell 150,000 shares at 8.2p, but only buy a maximum 10,000 shares at the maximum 10p offer.Plenty of demand out there it seems.
gretel
12 Jul 2016
Good buying interest online Online now a buyer will take an unusually large 140,000 shares at 8.1p, whilst I can only buy a maximum 40,000 shares.Any buying interest would probably move the price - and the spread - quickly.
gretel
11 Jul 2016
Finncap 29p target : 190% upside Finncap reiterate their 29p target today:[link]
gretel
11 Jul 2016
Great RNS this morning Excellent ProReveal news confirmed by SDI this morning! ProReveal obviously has not only huge blue sky potential, but is near-term too.Yet with the core business forecast to make 1.5p EPS, and with SDI's cash pile too, ProReveal is in the price for free:[link] particular...."ProReveal, our highly sensitive fluorescence-based patented protein detection test, is the only marketed product of which we are aware that can adhere to these stringent guidelines"And:"It is a goal that all healthcare providers engaged in the management and decontamination of surgical instruments used in acute care will be expected to have implemented this guidance by 1 July 2018. However, providers whose instruments are likely to come into contact with higher risk tissues, for example neurological tissue, are expected to give this guidance higher priority and move to in situ protein detection methodologies by 1 July 2017."
gretel
28 Jun 2016
SDI benefit from the pound's fall Around 88% of SDI's revenues derive from abroad, including 53% from the USA and Asia.This year's and future numbers could benefit in a big way from the pound's fall.
gretel
31 May 2016
Octopus VCT invests in SDI FYI last Friday's results from Octopus AIM VCT contained a snippet that they've invested £179,000 into SDI, presumably via the Nov'14 acquisition fundraising.SDI were the only profitable company they invested in of their five new investments![link]
gretel
24 May 2016
Moving up today on trading update Excellent trading update showing historic results in line with 1.5p EPS expectations:[link] this morning also forecast £0.8m adjusted PBT and £1m net cash against a £6m m/cap.For this year they expect £1.1m adjusted PBT and 1.6p EPS.At an 11p share price SDI look extremely cheap AND have a very sound Balance Sheet.New(ish) management have now transformed the company, and Sentek has brought in good recurring revenues and increased profitability.I'd anticipate further acquisitions soon given the cash pile.This is just the start of the journey imho. There could be a long way to go.
Simbrad
24 May 2016
Read finnCap's note on SDI, out this morning on Research Tree: "The company has released a trading update for the full year to 30 April 2016, stating that statutory pre-tax profit is in line with expectations and that the acquisition of Sentek in October 2015 has met management expectations. Final results will be released in July. Trading statement in line with expectations. The Board has indicated that it expects reported profit before tax for the year ending 30 April 2016 to be in line with expectations. Our forecasts are for a statutory PTP of £0.5m. Adjusted pre-tax profits are expected to be c£0.8m, an increase of 123% over FY 2015..."
gretel
27 Apr 2016
Very little stock available The 133,000 buy at 11p (and an earlier small top-up from me at 9.95p) took out all the available stock - now there's only small amounts available again at 11p.
gretel
19 Apr 2016
Incredible shareholder list As well as Miton, Octopus and Patrick Evershed, Christopher Mills has also taken almost 8% of SDI via his Harwood Capital vehicle:[link] SDI shareholder list is now something to behold for a £6.4m microcap:Shareholder Number of ordinary shares Percentage of issued share capital Octopus 7,706,430 12.01 Herald Investment Management 5,436,667 8.47 Harwood Capital 4,991,286 7.78 Milton Asset Management 4,991,286 7.78 Hargreave Hale 4,748,852 7.40 Dana Investments 3,496,494 5.45 Charles Stanley 3,051,631 4.76 Walker Crips 2,338,145 3.64
gretel
18 Apr 2016
ProReveal making good progress It seems ProReveal has been making good progress - the last paragraph is particularly encouraging:[link] surgery clean 29 Jan 2016Synoptics innovative ProReveal test machinesMidas Pattern Company are moulding stylish cover sets for test machines that serve to verify the cleanliness of surgical instruments after disinfection.The company’s services such as FASTrim rapid prototyping and MRIM production moulding have helped ensure Synoptics innovative ProReveal test machines remain clean.Richard Hopwood, R&D manager at Synoptics, said: “We worked closely with well-known academic research facilities on the cleanliness of surgical instruments based on conventional swab tests.� “The research proved that swab testing is not always sufficient. As a result we set about creating a test machine that could detect protein at much lower levels using extremely sensitive camera technology in combination with innovative lighting and filters,� he added. The ProReveal is a fluorescence-based, patented, protein detection test for checking the presence of residual protein on surgical instruments after going through a washer disinfector process. ProReveal can detect less than 50ng of residual protein, with results produced in under 5 minutes. The test delivers objective, visual and measurable results, removing doubt as to whether the washing decontamination process has left instruments demonstrably clean. To ensure that the design of this advanced product matched the high expectations of its concept, Synoptics turned to established product design partner, LA Design. “The high resolution cameras being proposed for ProReveal can see an astonishing level of detail, but only if the illumination is correct – as a result, the covers have to be light-tight, which demands precision,� explained Les Stokes, one of the founders of LA Design. He added: “Beyond fit and function, the covers not only have to look stylish and approachable, but also have to relate to other products in the range, and help build the brand using an easy-to-understand design language.� These factors let to LA Design turning to Midas for the manufacture of the covers, a toolmaker and moulding shop it had used successfully before on a number of high profile projects. “Timing was another issue as not only was Synoptics Health looking to get to market first, but the product was scheduled to appear at a forthcoming exhibition,� said Mr Stokes. “From previous experience we knew that Midas delivered good service, both on-time and of good quality.� With the prototype parts having served their purpose, production moulding is now being offered by Midas’ unique composite resin tooling system, which is used to produce high quality polyurethane mouldings. The set of covers for the ProReveal test machine comprise a number of separate mouldings that face the user, including a drawer. A number of ProReveal machines are now operating in the field, predominantly at the site of washing system manufacturers keen to demonstrate that their technology works."
gretel
13 Apr 2016
Big re-rating possible here? SDI are imo on the cusp of a big turnaround, expedited by the big Sentek acquisition and some now outstanding institutional shareholders.This terrific article by Private Punter summarises things nicely:[link] Punter: SDI results show organic growth Cambridge News | Posted: January 08, 2016 Martin FlittonScientific Digital Imaging (SDI) based at Nuffield Road here in Cambridge, has today announced its Interim results for the period ended 31 October 2015. Although the figures exclude the potentially transformational acquisition of Sentek, which was concluded a just a few days prior to period end, the numbers demonstrate continued progress within existing operations where organic growth of 15% was registered over the corresponding period. This was largely driven by Synoptics the largest division within the group, along with the Atik arm which serving the astronomy market now accounts for 25% of sales. Both played a part in assisting the jump in revenue from last years six months £3.18m to £3.67m, which also saw EBITDA increase by 69.8% to 0.4M. As for profits, the adjusted figure came out at £189k against the previous loss of £20k and would appear to set the company on track, for a full year in-line with Broker FinnCap's estimates of adjusted pre-tax profit of £0.7m. Although the reported period shows a net debt position of £1.4m due to costs incurred within the Sentek acquisition, that has since been eradicated due to the companies successful placing raising £2.5m post the period end. Looking ahead, SDI should now begin to benefit from Sentek's contribution, having previously stated that the Braintree based operation should provide it with repeat business in consumables bringing some welcome recurring revenue, along with an opportunity to leverage with existing distributors. There was also some other potentially interesting points to note, the first being a new version of the software for ProtoCOL 3 having been released, which provides the addition of testing for antibiotic resistance susceptibility. The same division is also developing a new system titled ChromaZona which is targeting antibiotic resistance testing in a clinical laboratories and is already undergoing clinical certification. Given the wide scale and growing concerns across this area there is clearly potential for SDI to capitalise on a growing market that includes hospital labs amongst others. Additionally, ProReveal which has largely been on the back burner, has it appears, made some progress at last and is not only being actively marketed but appears to have made some sales. The Department of Health publishing new acceptable limits of protein contamination on re-usable surgical instruments could at last see some welcome progress within the UK health market which would assist some early sales achieved in the US. With SDI expecting Sentek to be earning enhancing in the first full year of ownership, the real turning point should feed through in next years numbers, where FinnCap forecasts revenue of £10.3m and adjusted profits of £1m to be registered. That would deliver EPS of 2.4p according to the Broker, placing the shares on a 2017 PER of under 5 at the current price of 11.5p. For now, the year in progress is expected to deliver revenues of £8.9m and adjusted pre-tax profits of £0.7m giving EPS of 1.7p, which PER of under 7. Having seen the likes of Gervais Williams (Miton), Octopus and a couple of other well known names come on board via the placing, SDI appears to have registered some decent support in its ambition of at last growing the business. The plan now appears to be to drive both existing operations and new business forward, along with a firm commitment to further earning enhancing acquisitions along the way to boost growth and profitability. Still in the sp
